Literature DB >> 17680617

Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy.

Claudia Stöllberger1, Josef Finsterer.   

Abstract

Restrictive cardiomyopathy (RCMP) is characterized by restrictive filling and reduced diastolic volume of either or both ventricles with normal or near-normal systolic function and wall thickness. It may occur idiopathically or as a cardiac manifestation of systemic diseases such as scleroderma, amyloidosis, Churg-Strauss syndrome, cystinosis, sarcoidosis, lymphoma, Gaucher's disease, hemochromatosis, Fabry's disease, pseudoxanthoma elasticum, hypereosinophilic syndrome, carcinoid, Noonan's syndrome, reactive arthritis, or Werner's syndrome and various neuromuscular disorders. Whereas in idiopathic RCMP the therapeutic options are only treatment of cardiac congestion, in cases with an underlying disorder, a causal therapy may be available. Patients with RCMP should be investigated as soon as the cardiac diagnosis is established for extracardiac diseases to detect a possibly treatable cause of RCMP before the disease becomes intractable. These investigations include a diligent clinical history and examination, blood tests, and ophthalmologic, otologic, dermatologic, gastroenterologic, nephrologic, hematologic, and neurologic examinations. If extracardiac examinations do not reveal a plausible cause for RCMP, endomyocardial biopsy is indicated. (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680617      PMCID: PMC6653654          DOI: 10.1002/clc.20005

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  74 in total

Review 1.  Approach to gene therapy of glycogenosis type II (Pompe disease).

Authors:  L Poenaru
Journal:  Mol Genet Metab       Date:  2000-07       Impact factor: 4.797

2.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy.

Authors:  N M Ammash; J B Seward; K R Bailey; W D Edwards; A J Tajik
Journal:  Circulation       Date:  2000-05-30       Impact factor: 29.690

3.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies.

Authors:  Kenneth R Chien
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  [Bilateral phrenic nerve paralysis, dysautonomia and restrictive cardiomyopathy in a case of POEMS syndrome].

Authors:  S Delalande; T Stojkovic; C Rose; A Millaire; J F Hurtevent; P Vermersch
Journal:  Rev Neurol (Paris)       Date:  2002-07       Impact factor: 2.607

5.  Clinical and molecular studies of a large family with desmin-associated restrictive cardiomyopathy.

Authors:  J Zhang; A Kumar; H J Stalker; G Virdi; V J Ferrans; K Horiba; F J Fricker; M R Wallace
Journal:  Clin Genet       Date:  2001-04       Impact factor: 4.438

6.  Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey.

Authors:  K Miura; H Nakagawa; Y Morikawa; S Sasayama; A Matsumori; K Hasegawa; Y Ohno; A Tamakoshi; T Kawamura; Y Inaba
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

7.  Surgery for endomyocardial fibrosis revisited.

Authors:  F Moraes; C Lapa; S Hazin; E Tenorio; C Gomes; C R Moraes
Journal:  Eur J Cardiothorac Surg       Date:  1999-03       Impact factor: 4.191

8.  Single large-scale mitochondrial DNA deletion in a patient with encephalopathy, cardiomyopathy, and prominent intestinal pseudo-obstruction.

Authors:  Y Campos; M A Martín; C Caballero; J C Rubio; F de la Cruz; T Tuñón; J Arenas
Journal:  Neuromuscul Disord       Date:  2000-01       Impact factor: 4.296

9.  [Pathology of heart transplantation.(Morphological study of 1246 endomyocardial biopsies from 167 transplanted hearts). Causes of early, intermediate, and late deaths].

Authors:  L Agozzino; K Thomopoulos; S Esposito; M Agozzino; F De Vivo; C Maiello; M Cotrufo
Journal:  Pathologica       Date:  1999-04

10.  Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up.

Authors:  Mehul P Dixit; Ira Greifer
Journal:  BMC Nephrol       Date:  2002-11-09       Impact factor: 2.388

View more
  6 in total

Review 1.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

2.  Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Clin Res Cardiol       Date:  2009-02-09       Impact factor: 5.460

Review 3.  Translating emerging molecular genetic insights into clinical practice in inherited cardiomyopathies.

Authors:  Babken Asatryan; Argelia Medeiros-Domingo
Journal:  J Mol Med (Berl)       Date:  2018-08-20       Impact factor: 4.599

4.  A retro-inverso TAT-like peptide designed to deliver cysteamine to cells.

Authors:  Jongdoo Lim; Jean-Philippe Pellois; Eric E Simanek
Journal:  Bioorg Med Chem Lett       Date:  2010-07-15       Impact factor: 2.823

5.  Cardiac amyloidosis: can advances in diagnostics and treatments improve survival?

Authors:  Kalai Karthikeyan; Nilesh Jagjivan; Matthew Lyttelton; James Cullen
Journal:  BMJ Case Rep       Date:  2009-08-17

Review 6.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.